Skip to main content

Table 1 Characteristics of patients > 50 years old hospitalized for community-acquired pneumonia all cause, overall and by age group, and for pneumococcal community-acquired pneumonia

From: The impact of comorbidities and their stacking on short- and long-term prognosis of patients over 50 with community-acquired pneumonia

Characteristics of the patients (n (% of overall))

CAP > 50 y.o.

(149,555 (100%))

P-CAP > 50 y.o.

(8270 (5.53%))

CAP 50–69 y.o.

(37,807(25.3%))

CAP 70–89 y.o.

(85,159 (56.9%))

CAP ≥ 90 y.o.

(26,589 (17.8%))

Male gender

78,862 (52.7%)

4794 (58.0%)

23,510 (62.2%)

45,753 (53.7%)

9599 (36.1%)

Age (years)

78.1 (12.0)

73.7 (12.4)

60.9 (5.5)

81.2 (5.4)

92.9 (2.8)

Alcohol

12,614 (8.4%)

1187 (14.4%)

6,980 (18.5%)

5234 (6.15%)

400 (1.50%)

Tobacco

18,225 (12.2%)

1912 (23.1%)

10,151 (26.8%)

7530 (8.84%)

544 (2.05%)

No comorbidity

10,847 (7.3%)

570 (6.89%)

6,333 (16.8%)

3620 (4.25%)

894 (3.36%)

HR comorbidities

50,587 (33.8%)

2962 (35.8%)

14,137 (36.8%)

29,732 (34.9%)

6718 (25.3%)

Solely HR comorbidities

3349 (2.24%)

201 (2.4%)

1898 (5.02%)

1301 (1.53%)

150 (0.56%)

No HR comorbidity

98,968 (66.2%)

5308 (64.2%)

23,670 (62.6%)

55,427 (65.1%)

19,871 (74.7%)

One HR comorbidity

42,670 (28.5%)

2423 (29.3%)

11,432 (30.2%)

25,203 (29.6%)

6035 (22.7%)

 ≥ 2 HR comorbidities

7917 (5.29%)

539 (6.5%)

2705 (7.15%)

4,529 (5.32%)

683 (2.57%)

Number of HR comorbidities

0.40 (0.62)

0.44 (0.66)

0.47 (0.69)

0.41 (0.62)

0.28 (0.51)

Solid tumor

36,540 (24.4%)

2042 (24.7%)

9885 (26.2%)

21,717 (25.5%)

4938 (18.6%)

Hematological malignancy

10,693 (7.15%)

705 (8.52%)

2491 (6.59%)

6736 (7.91%)

1466 (5.51%)

Auto-immune disorders

6731 (4.50%)

384 (4.64%)

1860 (4.92%)

4113 (4.83%)

758 (2.85%)

Primitive immune deficiency

2392 (1.60%)

187 (2.26%)

957 (2.53%)

1276 (1.50%)

159 (0.60%)

Organ transplant recipient

2298 (1.54%)

153 (1.85%)

1567 (4.14%)

654 (0.77%)

77 (0.29%)

HIV

698 (0.47%)

91 (1.10%)

578 (1.53%)

118 (0.14%)

2 (0.01%)

Asplenia—hyposplenia

636 (0.43%)

705 (8.52%)

266 (0.70%)

324 (0.38%)

46 (0.17%)

AR comorbidities

135,359 (90.5%)

7499 (90.7%)

29,576 (78.2%)

80,238 (94.2%)

25,545 (96.1%)

Solely AR comorbidities

88,121 (58.9%)

4738 (57.3%)

17,337 (45.9%)

51,807 (60.8%)

18,977 (71.4%)

No AR comorbidity

14,196 (9.5%)

771 (9.32%)

8231 (21.8%)

4921 (5.78%)

1044 (3.93%)

One AR comorbidity

32,150 (21.5%)

1819 (22.0%)

10,547 (27.9%)

16,646 (19.5%)

4957 (18.6%)

2 AR comorbidities

41,724 (27.9%)

2537 (30.7%)

9295 (24.6%)

24,531 (28.8%)

7898 (29.7%)

3 AR comorbidities

33,826 (22.6%)

1862 (22.5%)

5802 (15.3%)

20,976 (24.6%)

7048 (26.5%)

 ≥ 4 AR comorbidities

27,659 (18.5%)

1281 (15.5%)

3932 (10.4%)

18,085 (21.2%)

5642 (21.2%)

Number of AR comorbidities

2.27 (1.39)

2.19 (1.32)

1.69 (1.36)

2.45 (1.35)

2.51 (1.28)

Chronic cardiac diseases

115,702 (77.4%)

6118 (74.0%)

21,630 (57%)

70,749 (83.1%)

23,323 (87.7%)

Malnutrition

52,338 (35.0%)

2651 (32.1%)

8819 (23.3%)

30,732 (36.1%)

12,787 (48.1%)

Chronic respiratory diseases

45,696 (30.6%)

3782 (45.7%)

12,710 (33.6%)

27,124 (31.9%)

5862 (22.1%)

Diabetes mellitus

35,250 (23.6%)

1905 (23.0%)

8067 (21.3%)

22,917 (26.9%)

4266 (16.0%)

Neurodegenerative diseases

30,027 (20.1%)

848 (10.3%)

1929 (5.10%)

20,246 (23.8%)

7852 (29.5%)

Chronic kidney diseases

28,074 (18.8%)

1281 (15.5%)

3832 (10.1%)

17,271 (20.3%)

6971 (26.2%)

Stroke

24,605 (16.5%)

874 (10.6%)

3367 (8.9%)

16,187 (19.0%)

5051 (19.0%)

Chronic liver diseases

7599 (5.08%)

651 (7.87%)

3466 (9.2%)

3631 (4.26%)

502 (1.89%)

HR and AR comorbidities

 ≥ 1 HR and ≥ 1 AR

47,238 (31.6%)

2761 (33.4%)

12,239 (32.4%)

28,431 (33.4%)

6568 (24.7%)

  1. CAP community-acquired pneumonia, P-CAP pneumococcal community-acquired pneumonia, HR high-risk comorbidities (immunodepression, immunodeficiency, cancer), AR at risk comorbidities (comorbidities at risk of pneumococcal CAP in immunocompetent patients), HIV human immunodeficiency virus, Q1–Q3 interquartile range. Qualitative variables are expressed as number of patients (percentages), quantitative variables as mean (SD)